Compare ARBB & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARBB | APVO |
|---|---|---|
| Founded | 1997 | 2016 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.3M |
| IPO Year | 2022 | 2023 |
| Metric | ARBB | APVO |
|---|---|---|
| Price | $4.80 | $4.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 4.1K | ★ 13.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,114,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $0.50 |
| 52 Week High | $13.89 | $10.70 |
| Indicator | ARBB | APVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 41.75 |
| Support Level | $4.50 | $4.36 |
| Resistance Level | $5.16 | $4.80 |
| Average True Range (ATR) | 0.31 | 0.23 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 27.69 | 41.33 |
ARB IOT Group Ltd is a provider of complete solutions to the clients for the integration of Internet of Things (IoT) systems and devices from designing to project deployment. The company offers a wide range of IoT systems as well as provides customers with a substantial range of services such as system integration and system support services. It delivers solutions like designing, installation, testing and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company operates in two reportable segments: (i) the provision of hardware and software of IoT solutions and (ii) Investment holding and others. The majority of revenue is generated from the IoT solutions segment.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.